Aptinyx Reports Third Quarter 2019 Financial Results and Highlights
12 nov. 2019 16h01 HE
|
Aptinyx Inc.
Initiated two Phase 2 studies of NYX-2925 in chronic pain conditions On track to have four Phase 2 studies ongoing by year end across pipeline of CNS product candidates Conference call today at 5:00...
Aptinyx to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
05 nov. 2019 08h07 HE
|
Aptinyx Inc.
EVANSTON, Ill., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
23 sept. 2019 17h27 HE
|
Schall Law
LOS ANGELES, Sept. 23, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc....
Aptinyx Reports Second Quarter 2019 Financial Results and Highlights
12 août 2019 06h33 HE
|
Aptinyx Inc.
Reported that NYX-2925 met primary and secondary endpoints in Phase 2 fibromyalgia study On track to initiate three additional Phase 2 studies in 2H 2019 across pipeline of CNS product candidates ...
Aptinyx Appoints Henry Gosebruch to Its Board of Directors
07 mai 2019 07h23 HE
|
Aptinyx Inc.
EVANSTON, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers
30 avr. 2019 07h27 HE
|
Aptinyx Inc.
Favorable overall safety, tolerability, and pharmacokinetic profile—no serious adverse events reported across wide dose range Achieved ample CNS exposure consistent with exposure observed at...
Aptinyx Presents Preclinical Data from Fast-Track Designated PTSD Program at Military Health System Research Symposium
21 août 2018 06h35 HE
|
Aptinyx Inc.
EVANSTON, Ill., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx Reports Second Quarter 2018 Financial and Business Results
14 août 2018 06h27 HE
|
Aptinyx Inc.
EVANSTON, Ill., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx Initiates Phase 1 Study of NYX-458
02 août 2018 08h00 HE
|
Aptinyx Inc.
EVANSTON, Ill., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...